Literature DB >> 2508254

Immunoreactivity of tissue plasminogen activator and of its inhibitor complexes. Biochemical and multicenter validation of a two site immunosorbent assay.

M Rånby1, G Nguyen, P Y Scarabin, M Samama.   

Abstract

An enzyme linked immunosorbent assay (ELISA) based on goat polyclonal antibodies against human tissue plasminogen activator (tPA) was evaluated. The relative immunoreactivity of tPA in free form and tPA in complex with inhibitors was estimated by ELISA and found to be 100, 74, 94, 92 and 81% for free tPA and tPA in complex with PAI-1, PAI-2, alpha 2-antiplasmin and C1-inhibitor, respectively. Addition of tPA to PAI-1 rich plasma resulted in rapid and total loss of tPA activity without detectable loss of ELISA response, indicating an immunoreactivity of tPA in tPA/PAI-1 complex of about 100%. Three different treatments of citrated plasma samples (acidification/reneutralization, addition of 5 mM EDTA or of 0.5 M lysine) prior to determination by ELISA all resulted in increased tPA levels. The fact that the increase was equally large in all three cases along with good analytical recovery of tPA added to plasma, supported the notion that all tPA antigen present in plasma samples is measured by the ELISA. Analysis by ELISA of fractions obtained by gel filtration of plasma from a patient undergoing tPA treatment identified tPA/inhibitor complexes and free tPA but no low molecular weight degradation products of tPA. Determinations of tPA antigen were made at seven French clinical laboratories on coded and randomized plasma samples with known tPA antigen content. For undiluted samples there was no significant difference between the tPA levels found and those known to be present. The between-assay coefficient of variation was 7 to 10%. In conclusion, the ELISA appeared suited for determination of total tPA antigen in human plasma samples.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2508254

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  6 in total

1.  The impaired fibrinolytic capacity in hypertension is unaffected by acute blood pressure lowering.

Authors:  Wilhelm Ridderstråle; Ott Saluveer; Maria Carlström; Sverker Jern; Thórdís J Hrafnkelsdóttir
Journal:  J Thromb Thrombolysis       Date:  2011-11       Impact factor: 2.300

2.  A Common Calibrator Does Not Secure Harmonisation of Commercial t-PA and PAI-1 Antigen Measurements.

Authors:  Moniek P M de Maat; Jorgen Gram; Jorgen Jespersen; Cornelis Kluft
Journal:  EJIFCC       Date:  2001-07-22

3.  Combination Therapy Using tPA and Edaravone Improves the Neurotoxic Effect of tPA.

Authors:  T Kano; T Harada; T Hirayama; Y Katayama
Journal:  Interv Neuroradiol       Date:  2007-06-27       Impact factor: 1.610

4.  Age-related effects of regular physical activity on hemostatic factors in men.

Authors:  Jun Sugawara; Koichiro Hayashi; Sumiko Kurachi; Taku Tanaka; Takashi Yokoi; Kotoku Kurachi
Journal:  J Thromb Thrombolysis       Date:  2007-09-10       Impact factor: 2.300

5.  Alterations in plasminogen activation correlate with epithelial cell dysplasia grading in colorectal adenomas.

Authors:  P Protiva; I Sordat; P Chaubert; E Saraga; C Trân-Thang; B Sordat; A L Blum; G Dorta
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

6.  Phorbol ester induced osteoclast-like differentiation of a novel human leukemic cell line (FLG 29.1).

Authors:  V Gattei; P A Bernabei; A Pinto; R Bezzini; A Ringressi; L Formigli; A Tanini; V Attadia; M L Brandi
Journal:  J Cell Biol       Date:  1992-01       Impact factor: 10.539

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.